Report Ocean presents a new report on subdermal contraceptive implants market size, share, growth, industry trends, and forecast 2030, covering various industry elements and growth trends helpful for ...
Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
Vivani Medical, Inc. (NASDAQ:VANI) announced that the U.S. FDA has cleared its Investigational New Drug Application for NPM-119, paving the way for the commencement of the LIBERATE-1 Phase 1 trial.
NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...
A woman in her late 30s presented with a complaint of not being able to palpate the subdermal contraceptive implant in her left arm, which was inserted 6 years earlier. An x-ray revealed a ...
That’s based on the 2024 subdermal implant service fee of $93.41. Indiana’s Medicaid program reimbursed nearly 40,000 live births in 2022, according to the analysis, but a fraction of patients are ...
There are three progestin-containing subdermal implants. The first implant to be developed was Norplant, which is no longer being manufactured. Norplant had six levonorgestrel-containing capsules, and ...
A Cochrane Systematic Review that set out to assess the effectiveness and tolerability of subdermal implantable contraceptives compared to other reversible methods of contraception found that they ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results